BioSpace News Archive

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce that its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine (“DMT”) has completed dosing for four out of five participant cohorts and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2022, and provided an overview of recent developments.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today shared highlights of new data being presented at the Society of Vascular and Interventional Neuroradiology (SVIN) in Los Angeles next week, demonstrating the significant impact of Viz ANEURYSM at a large hospital system.

Gamida Cell Ltd. today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the Jefferies London Healthcare Conference, November 17, 2022 with a presentation at 9:10 a.m. GMT.

Sonoma Biotherapeutics, Inc. will be presenting key data at the American College of Rheumatology (ACR) Convergence 2022 Scientific Sessions highlighting preclinical data from the company’s autologous T reg therapy for the treatment of rheumatoid arthritis (RA).

Equillium, Inc. today announced that it has initiated a Phase 2 open-label study of EQ101 to assess efficacy and safety in adult subjects with moderate to severe alopecia areata.

Global molecular diagnostics innovator Sense Biodetection (Sense) today announced it has entered into a strategic agreement with Bio Nuclear Diagnostics, Inc. (BND) for the non-exclusive distribution in Canada of Sense’s Veros instrument-free, point-of-care molecular testing platform.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD) (OTCQB: SQIDF) today announced that it has entered into a funding agreement (the “Contribution Agreement”) with the Federal Economic Development Agency for Southern Ontario (“FedDev Ontario”) to support the Company’s manufacturing scale-up and commercialization of its pipeline of products in development, including the Company’s recently approved RALI-DX IL-6 test.

AbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.

Acacia Research Corporation (Nasdaq: ACTG) (“Acacia” or the “Company”) today reported financial results for the three and nine months ended September 30, 2022.